Article

Pembrolizumab Plus Chemotherapy Drives Durable PFS, OS Benefit in Squamous NSCLC

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.

Silvia Novello, MD, PhD

Silvia Novello, MD, PhD

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival (PFS) and overall survival (OS) vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer (NSCLC) regardless of PD-L1 expression level, according to 5-year data from the phase 3 KEYNOTE-407 trial (NCT02775435).

Data presented at the 2022 ESMO Congress showed that at a median follow-up of 56.9 months (range, 49.9-66.2), the median OS was 17.2 months (95% CI, 14.4-19.7) with pembrolizumab vs 11.6 months (95% CI, 10.1-13.7) with placebo (HR, 0.71; 95% CI, 0.59-0.85). The 5-year OS rates in the investigative and control arms were 18.4% and 9.7%, respectively.

The median PFS was 8.0 months (95% CI, 6.3-8.5) with pembrolizumab vs 5.1 months (95% CI, 4.3-6.0) with placebo (HR, 0.62; 95% CI, 0.52-0.74). The 5-year PFS rates in the investigative and control arms were 10.8% and 3.5%, respectively.

“Long-term data continue to support pembrolizumab plus chemotherapy as a standard-of-care first-line treatment option for metastatic squamous NSCLC,” lead study author Silvia Novello, MD, PhD, professor of medical oncology at the University of Turin, said in a presentation of the data.

Significant improvements in PFS and OS were previously reported with pembrolizumab vs placebo in findings from the primary (OS: HR, 0.64; 95% CI, 0.49-0.85; P < .001; PFS: HR, 0.56; 95% CI, 0.45-0.70; P < .001) and protocol-specified final analysis (OS: HR, 0.71; 95% CI, 0.58-0.88; PFS: HR, 0.57; 95% CI, 0.47-0.69) of the trial, which had been conducted at median follow-ups of 7.8 (range, 0.1-19.1) and 14.3 (range, 0.1-31.3) months, respectively.

At approximately 5 years, 50.9% (n = 117) of patients on the placebo arm had crossed over to receive pembrolizumab monotherapy on study and another 26 received subsequent anti–PD-(L)1 therapy off study.

Additional results showed that patients derived benefit from pembrolizumab regardless of whether they had PD-L1 expression below 1% (OS: HR, 0.83; 95% CI, 0.61-1.13; PFS: HR, 0.70; 95% CI, 0.52-0.95), between 1% and 49% (OS: HR, 0.61; 95% CI, 0.45-0.83; PFS: HR, 0.60; 95% CI, 0.45-0.81), or 50% or greater (OS: HR, 0.68; 95% CI, 0.47-0.97; PFS: HR, 0.48; 95% CI, 0.33-0.69).

In the intention-to-treat population, the objective response rate (ORR) was 62.2% with pembrolizumab (n = 278) vs 38.8% with placebo (n = 281). The median duration of response (DOR) in this population was 9.0 months (range, 1.3+ to 61.5+) with pembrolizumab vs 4.9 months (range, 1.3+ to 58.6+) with placebo.

Responses were similarly improved with pembrolizumab vs placebo in patients with PD-L1 expression below 1% (67.4% vs 41.4%), between 1% and 49% (54.4% vs 43.3%), and 50% or greater (64.4% vs 30.1%). The median DOR was also prolonged with pembrolizumab in each PD-L1 subset.

Notably, patients who completed all 35 cycles of pembrolizumab (n = 55) had “durable responses and experienced long-term OS,” Novello said. In this population, the ORR was 90.9% (95% CI, 80.0%-97.0%) and consisted of 9 (16.4%) complete responses and 41 (74.5%) partial responses. The median DOR in this population was not yet reached (range, 7.1-61.5+).

Additionally, the 3-year OS rate after completing 35 cycles of pembrolizumab was 69.5%, and 43.6% (n = 24) of patients were alive without progressive disease or subsequent therapy.

Regarding safety, 98.6% of those in the pembrolizumab arm (n = 278) experienced any adverse effects (AEs) vs 98.2% of those in the placebo arm (n = 280); these cases were grade 3 to 5 in 74.8% and 70.0% of patients, respectively. Immune-mediated toxicities occurred in 35.6% of those in the investigative arm vs 9.3% of those in the control arm; these effects were grade 3 to 5 in 13.3% and 3.2% of patients, respectively.

In the pembrolizumab arm, 28.8% of patients experienced toxicities that resulted in discontinuation of any treatment, 17.2% experienced AEs that led to discontinuation of all treatments, and 11.5% experienced AEs that resulted in death.

“Toxicity was manageable and consistent with prior reports from KEYNOTE-407,” Novello concluded.

Reference

Novello S, Kowalski DM, Luft A, et al. 5-year update from KEYNOTE-407: pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer. Ann Oncol. 2022;33(suppl 7):S993-S994. doi:10.1016/j.annonc.2022.07.1102

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD